Basel Medical Group Ltd (BMGL) FinancialsBMGLBasel Medical Group Ltd

Evaluating the bottom line, Basel Medical Group Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -10.76%, while the net margin is 1.94%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BMGL converts its operational activities into shareholder value.

In the context of the broader market, BMGL competes directly with industry leaders such as PRPO and RYOJ. With a market capitalization of $70.48M, it holds a leading position in the sector. When comparing efficiency, BMGL's gross margin of 100.00% stands against PRPO's 44.67% and RYOJ's 26.47%. Such benchmarking helps identify whether Basel Medical Group Ltd is trading at a premium or discount relative to its financial performance.

The company has reported a gross margin of 100% in recent quarters, indicating strong profitability on sales. However, it has also experienced net losses, with an EPS of -0.21 in Q2 2025 and -0.57 in Q4 2025, before turning positive with an EPS of 0.10 in Q2 2026, showing signs of recovery.